Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study

Ana Rosa Rubio-Salvador, Vicente Escudero-Vilaplana, José Antonio Marcos Rodríguez, Irene Mangues-Bafalluy, Beatriz Bernardez, Carlos García Collado, Roberto Collado-Borrell, María Dolores Alvarado Fernández, José Ignacio Chacón López-Muñiz, María Yébenes Cortés, Manuel Gómez Barrera and Miguel Ángel Calleja-Hernández
Additional contact information
Ana Rosa Rubio-Salvador: Servicio de Farmacia, Complejo Hospitalario de Toledo, 45004 Toledo, Spain
Vicente Escudero-Vilaplana: Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
José Antonio Marcos Rodríguez: Servicio de Farmacia, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
Irene Mangues-Bafalluy: Servicio de Farmacia, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain
Beatriz Bernardez: Servicio de Farmacia, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15706 A Coruña, Spain
Carlos García Collado: Servicio de Farmacia. Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain
Roberto Collado-Borrell: Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
María Dolores Alvarado Fernández: Servicio de Farmacia, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
José Ignacio Chacón López-Muñiz: Servicio de Oncología Médica, Complejo Hospitalario de Toledo, 45007 Toledo, Spain
María Yébenes Cortés: Pharmacoeconomics & Outcomes Research Iberia, 28224 Madrid, Spain
Manuel Gómez Barrera: Pharmacoeconomics & Outcomes Research Iberia, 28224 Madrid, Spain
Miguel Ángel Calleja-Hernández: Servicio de Farmacia, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain

IJERPH, 2021, vol. 18, issue 2, 1-9

Abstract: Background: Patients with lung cancer (LC) are at significantly higher risk of developing venous thromboembolism (VTE), which may lead to increased use of health resources and the cost of the disease management. The main aim of the study was to determine the cost of the management of VTE events in patients with LC treated with Low Molecular Weight Heparins (LMWH) in Spain. Methods: Costecat was an observational, ambispective pharmacoeconomic study. Patients with LC, with a first episode of VTE (symptomatic or incidental) in treatment with LMWH, were recruited from six third-level hospitals and followed up for six months. Sociodemographic, clinical and resource use variables of VTE-related implications and its treatment were collected. Direct healthcare costs and direct non-healthcare costs were recorded. Data collection was documented in an electronic case report. Costs (€2018) were estimated from the healthcare perspective. Statistical analysis was performed using the statistical program R 3.4.3 version (30 November 2017). Results: Forty-seven patients were included. Mean age was 65.4 years, 66.0% were male. The percentage of patients with LC who had metastatic disease was 78.7%. Twenty-three patients (48.9%) needed hospital admissions due to thromboembolic episode. Total average cost of patients with cancer associated VTE (CAT) was €10,969.6 per patient/semester. The hospitalizations represent 65.8% of total costs (7207.3 € SD 13,996.9 €), followed by LMWH therapy which represents 18.6% (2033.8 € SD:630.5 €). Conclusions: Venous thromboembolism episodes induce an economic impact on patients and healthcare systems. Direct healthcare costs are the major burden of the total cost, in which hospitalizations are the main drivers of cost.

Keywords: cancer; thromboembolic disease; LMWH; cost; economic impact (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/2/394/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/2/394/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:2:p:394-:d:475820

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().